Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 17/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 15/20 | 0.66 |
| ▸ | L3MBTL4 | Q8NA19 | 3/20 | 0.58 |
| ▸ | MBTD1 | Q05BQ5 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085278 | 0.83 | L3MBTL3 (0.65) | L3MBTL3L3MBTL1L3MBTL4MBTD1TP53BP1 | |
| SCHEMBL16151062 | 0.75 | LMNA (0.46) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL1083729 | 0.75 | L3MBTL1 (0.51) | L3MBTL3L3MBTL1L3MBTL4MBTD1MEN1 | |
| SCHEMBL1083699 | 0.75 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1L3MBTL4MBTD1MEN1 | |
| SCHEMBL23682705 | 0.75 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1L3MBTL4MBTD1MEN1 | |
| SCHEMBL3399366 | 0.74 | MEN1 (0.54) | MEN1KMT2A | |
| SCHEMBL2931560 | 0.74 | TSHR (0.54) | L3MBTL1KMT2AKDM4E | |
| SCHEMBL19730382 | 0.73 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1L3MBTL4MBTD1TP53BP1 | |
| SCHEMBL3396292 | 0.73 | LMNA (0.44) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3396285 | 0.73 | LMNA (0.44) | MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153805-B2 | Biaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2205583-A2 | N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009043747-A2 | N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | CCR3, CCRL2, CCR2 | L3MBTL3 1629/4885L3MBTL1 2710/4885L3MBTL4 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.